We’re pleased to have been welcomed to the cohort of the British Chambers of Commerce Trade Accelerator programme.
Developed to address the gap between ambition and execution in UK exports, the programme is a practical, outcomes-driven initiative focused on converting innovation into real international commercial success. It brings together UK industry, government, and in-market partners to support life sciences companies entering high-growth markets such as Singapore and Southeast Asia.
For us, this represents an important opportunity to extend British innovation globally and build meaningful commercial and research partnerships to support disease modeling, drug discovery, and translational research across multiple therapeutic areas.
What this means in practice:
- A structured, six-month programme designed to support entry into high-value international markets
- A practical 10-stage pathway guiding companies from early market exploration to commercial traction and signed deals
- Access to in-market expertise, partner networks, and commercial support to enable confident market entry
- Integrated support across regulatory navigation, market validation, and partnership development
- A coordinated “Team UK” approach, aligning Chambers, government, and financial partners
At Axol Bioscience, we develop human iPSC-derived cell models and tools to enable disease modeling, drug discovery, and translational research across multiple therapeutic areas. Participation in the Trade Accelerator supports our ambition to scale these capabilities internationally and contribute to the global life sciences ecosystem from a strong UK foundation.
Learn more: https://www.britishchambers.org.uk/trade-accelerator
Our Chief Business Officer, Catherine Elton, and Scientific Group Leader Jamie Bhagwan will be attending this week’s programme event, and we look forward to engaging with fellow cohort members and partners.
